Cdk-mediated striatal neuroadaptation in parkinsonism
Project Number1R15NS051270-01
Contact PI/Project LeaderOH-LEE, JUSTIN D
Awardee OrganizationCENTRAL MICHIGAN UNIVERSITY
Description
Abstract Text
DESCRIPTION (provided by applicant): Parkinson's disease (PD) is a neurodegenerative disorder currently afflicting nearly over one million Americans. Initially, treatment with levodopa (L-DOPA) or a direct dopamine agonist ordinarily confers substantial clinical benefit. Within a few years, however, repetitive administration of these drugs to PD patients ultimately leads to development of disabling motor response complications. Current evidence suggests that these response alterations involve activation of striatal signal transduction cascades causing upregulation of corticostriatal glutamatergic synaptic transmission which in turn modifies striatal output in ways that compromise motor behavior. FosB-mediated activation of cycline-dependent kinase 5 (Cdk5) has been increasingly implicated in the neuroadaptive mechanisms related to repeated psychostimulant administration in drug addiction. To elucidate molecular mechanisms that underlie the pathogenesis of motor response occurring with chronic L-DOPA treatment of parkinsonian animals, the time course of response shortening and the appearance of Abnormal Involuntary Movements (AIMs) is evaluated in relation to change in striatal Cdk5 and glutamatergic signaling in 6-hydroxydopamine lesioned rats. The striatal tissue from these animals is also evaluated for these biochemical changes by using Western blot, Immunoprecipitation and immunohistochemical analyses. The functional significance of striatal Cdk5 activation is then determined by assessing the ability of Cdk5 antisense and inhibitors to affect both the biochemical and motor response changes associated with chronic dopaminomimetic treatment and its subsequent withdrawal. Findings from the proposed studies can provide more accurate understanding of molecular mechanisms underlying striatal neuroadaptive plasticity contributing to the pathogenesis of LDOPA- induced genesis of maladaptive motor complications in advanced PD, and suggest novel approaches to safer and more effective therapy of extrapyramidal motor dysfunction and other dopamine disease states.
National Institute of Neurological Disorders and Stroke
CFDA Code
853
DUNS Number
624134037
UEI
JJDYK36PRTL5
Project Start Date
15-May-2005
Project End Date
31-August-2009
Budget Start Date
15-May-2005
Budget End Date
31-August-2009
Project Funding Information for 2005
Total Funding
$191,474
Direct Costs
$150,000
Indirect Costs
$41,474
Year
Funding IC
FY Total Cost by IC
2005
National Institute of Neurological Disorders and Stroke
$191,474
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R15NS051270-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R15NS051270-01
Patents
No Patents information available for 1R15NS051270-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R15NS051270-01
Clinical Studies
No Clinical Studies information available for 1R15NS051270-01
News and More
Related News Releases
No news release information available for 1R15NS051270-01
History
No Historical information available for 1R15NS051270-01
Similar Projects
No Similar Projects information available for 1R15NS051270-01